Saltar al contenido
Merck

Effect of alkalinisation of lignocaine for propofol injection pain: a prospective, randomised, double-blind study.

Anaesthesia and intensive care (2013-07-03)
U Ozgul, Z Begec, M A Erdogan, M S Aydogan, M Sanli, C Colak
RESUMEN

The aim of this study was to determine whether pretreatment with alkalinised lignocaine reduced the incidence and severity of pain during propofol injection. This prospective, randomised, double-blind study included 300 adult, American Society of Anesthesiologists physcial status I to II patients undergoing elective surgery. Patients were randomly allocated to one of three groups: Group L received 0.05 ml/kg of 1% lignocaine (5 ml normal saline + 5 ml 2% lignocaine), Group A received 0.05 ml/kg alkalinised lignocaine (5 ml 2% lignocaine + 1 ml 8.4% NaHCO3 + 4 ml normal saline), and Group S, the control group, was given the same amount of normal saline (NaCl 0.9%). All drugs were given as a bolus over 20 seconds before propofol administration. A blinded researcher assessed the patient's pain level using a four-point scale. The pain score [median (range)] and the incidence of pain in Group A (6%) was significantly lower than in groups L (41%) and S (88%, P <0.001). In addition, the pain score and the incidence of pain were found to be significantly different between Group L and Group S (P <0.001). The incidence of moderate and severe pain were greater in Group S when compared with groups A and L (P <0.001). Intravenous pretreatment with alkalinised lignocaine appears to be effective in reducing the pain during propofol injection.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Bicarbonato de sodio, ACS reagent, ≥99.7%
Sigma-Aldrich
Bicarbonato de sodio, powder, BioReagent, for molecular biology, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Bicarbonato de sodio, ReagentPlus®, ≥99.5%, powder
Sigma-Aldrich
Sodium bicarbonate solution, solution (7.5%), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Bicarbonato de sodio, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E500, 99.0-100.5%, powder
Sigma-Aldrich
Lidocaine hydrochloride monohydrate, solid
Sigma-Aldrich
2,6-Diisopropylphenol, 97%
Sigma-Aldrich
Bicarbonato de sodio, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99.5%
Supelco
Lidocaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Bicarbonato de sodio, BioXtra, 99.5-100.5%
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Bicarbonato de sodio, −40-+140 mesh, ≥95%
Supelco
Sodium bicarbonate concentrate, 0.1 M NaHCO3 in water, eluent concentrate for IC
Supelco
Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Propofol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Sodium bicarbonate-12C, 99.9 atom % 12C
Sigma-Aldrich
Bicarbonato de sodio, tested according to Ph. Eur.
Lidocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Propofol, European Pharmacopoeia (EP) Reference Standard
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard